NAS10030,808+1.00%S&P7,723+0.73%GOLD$4,184+0.52%BTC$86,009−0.55%VIX16.17+5.62%live tape · as of 13:03 UTC
The Screen · Healthcare · Biotechnology
CRISPR Therapeutics AG
CRSP · Nasdaq · USD · Market cap $5.4B
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein…
FAIL · Does not pass the screen
55.44 USD
Screen close, 2026-10-01 · not a live quote Last reviewed 4 days ago
Screened 2026-10-01 · the tape above runs as of 13:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 55.44 against the desk's fair-value range, base estimate 80.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price55.44 USD
Fair value80.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown55.44+0.0% to today
2026-08-25Read Markup51.64+7.4% to today ✓
2026-07-02Read Accumulation49.80+11.3% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
CRISPR Therapeutics AG holds its Markdown at $55.44. Consolidating, no directional conviction, held for 6 days.
As held on the ledger · 2026-10-01
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 6 days
Price at the screen
$55.44
Valuation
N/A trailing · -15.85 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.76
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
9.13%
Below 33%
Interest-bearing debt is just 9.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
71.88%
Below 33%
Interest-bearing cash and securities are 71.9% of assets, above the one-third limit.
Fail
Receivables
15.34%
Below 49%
Money owed to the company is 15.3% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
CRISPR Therapeutics's business is fine, but its cash and interest-bearing securities are about 72% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 44.3% margin of safety to the base estimate.
Third-party analyst targets: 18 covering, consensus Buy. The average target sits +44% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Gene editing looks clever but stays unprofitable
Picture a lab team rewriting DNA the way a coder patches software. CRISPR Therapeutics has the tools and early revenue growth of 69 percent, yet it still posts zero profit margins and a negative 31 percent return on equity. The market prices the shares at 47.78 dollars against an analyst median target of 80 dollars, but the opportunity rating stays at none because the business has not crossed into consistent cash generation.
We therefore pass. A forward price to earnings ratio of negative 12.3 times signals losses rather than value, and an unknown moat leaves the platform exposed once larger drug makers enter the same gene editing field. Ethical screens clear, yet the numbers do not meet our threshold for a durable investment case at this stage.
Risk sits in the clinical and regulatory path, where trial setbacks or delayed approvals can erase paper margins of safety quickly. Currency and funding cycles add further swings for a Swiss listed biotech that has yet to prove repeatable profits. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; its business and earnings are exposed to Switzerland and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CRSP trades on Nasdaq (the company is based in Switzerland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$55.44+7.4%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 7.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (21 analysts) rates it buy, with a mean price target of $82. Insiders have been net sellers over the past quarter.
2026-08-25Markup · changed$51.64+8.1%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (21 analysts) rates it buy, with a mean price target of $82.
2026-07-25Accumulation$47.78-4.1%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (21 analysts) rates it buy, with a mean price target of $82.
2026-07-18Accumulation$49.80+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 16%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (21 analysts) rates it buy, with a mean price target of $82.
2026-07-03Accumulation$49.80+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$49.80Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
